Literature DB >> 20164820

Characterization of rabbit antithymocyte globulins-induced CD25+ regulatory T cells from cells of patients with end-stage renal disease.

Varsha D K D Sewgobind1, Luc J W van der Laan, Marcia M L Kho, Rens Kraaijeveld, Sander S Korevaar, Thea van Dam, Jan N M Ijzermans, Willem Weimar, Carla C Baan.   

Abstract

BACKGROUND.: Rabbit antithymocyte globulins (rATGs) are known to convert CD4CD25FoxP3 T cells from healthy individuals to CD4CD25FoxP3 T cells. In this study, we investigated the effect of rATG on the induction of regulatory T cells (Tregs) from blood cells of patients with end-stage renal disease who are candidates for transplantation and rATG-induction therapy. The induced Tregs were analyzed and compared with naturally occurring CD4CD25FoxP3T cells. METHODS.: The CD25 T cells of pretransplant patients (n=7) and healthy controls (n=4) were stimulated with rATG or control rabbit immunoglobulins for 24 hr. The phenotype of induced Tregs was examined by flow cytometry, and their function was studied in the conventional suppression assay. Further characterization was performed by mRNA analyses. RESULTS.: After 24 hr, the percentage of CD4CD25FoxP3CD127 T cells and CD8CD25FoxP3CD127 T cells became higher in the rATG-treated samples compared with the rabbit immunoglobulin-treated samples (P<0.01). The rATG-induced CD25T cells, whether CD4 or CD8 inhibited the allogeneic responses of CD25 effector T cells as vigorously as natural CD25T cells. However, the proportion of FoxP3 within the top 2% rATG-induced CD4CD25T-cells was lower than within the natural CD4CD25T-cells (11%+/-2% vs. 95%+/-5%, P<0.01). The mRNA-expression levels of interleukin-27, interleukin-10, interferon-gamma, perforin, and granzyme B were markedly higher compared with natural CD25T-cells (all P=0.03), whereas CTLA4 (P=0.03), transforming growth factor-beta (P=0.02), and RORgammat (P=0.04) were lower. CONCLUSION.: rATG allows the induction of Tregs from patient peripheral blood mononuclear cell in vitro. In comparison with natural Tregs, the rATG-induced Tregs are phenotypically distinct but have similar regulatory activities. rATG may beneficially contribute to the mechanisms that control alloreactivity.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20164820     DOI: 10.1097/TP.0b013e3181c9cc7a

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  6 in total

1.  Confounding effect of cyclosporine dosing when comparing horse and rabbit antithymocyte globulin in patients with severe aplastic anemia.

Authors:  Nathalie Bleyzac; Michaël Philippe; Amandine Bertrand; Yves Bertrand
Journal:  Haematologica       Date:  2015-05       Impact factor: 9.941

2.  Ex vivo expansion of human Tregs by rabbit ATG is dependent on intact STAT3-signaling in CD4⁺ T cells and requires the presence of monocytes.

Authors:  O Boenisch; M Lopez; W Elyaman; C N Magee; U Ahmad; N Najafian
Journal:  Am J Transplant       Date:  2012-03-05       Impact factor: 8.086

Review 3.  Immunomodulation with rabbit anti-thymocyte globulin in solid organ transplantation.

Authors:  Giovanbattista Ippoliti; Marco Lucioni; Giuseppe Leonardi; Marco Paulli
Journal:  World J Transplant       Date:  2015-12-24

4.  Human adipose-tissue derived mesenchymal stem cells induce functional de-novo regulatory T cells with methylated FOXP3 gene DNA.

Authors:  A U Engela; M J Hoogduijn; K Boer; N H R Litjens; M G H Betjes; W Weimar; C C Baan
Journal:  Clin Exp Immunol       Date:  2013-08       Impact factor: 4.330

5.  Myeloid-derived suppressor cells are bound and inhibited by anti-thymocyte globulin.

Authors:  Young Suk Lee; Eduardo Davila; Tianshu Zhang; Hugh P Milmoe; Stefanie N Vogel; Jonathan S Bromberg; Joseph R Scalea
Journal:  Innate Immun       Date:  2019-01       Impact factor: 2.680

6.  Alemtuzumab as Antirejection Therapy: T Cell Repopulation and Cytokine Responsiveness.

Authors:  Anne P Bouvy; Mariska Klepper; Michiel G H Betjes; Willem Weimar; Dennis A Hesselink; Carla C Baan
Journal:  Transplant Direct       Date:  2016-05-25
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.